Glioblastoma multiforme (GBM) is the most malignant brain tumor in adults. GBM is characterized as a tumor with a poor prognosis, and GMB bearing patients have a low survival rate. Artesunate (ART) is currently used as an anti-malarial drug and has many anti-cancer activities. ART has been shown to cause a profound cytotoxic effect on different cancer cell lines, presenting a new candidate for cancer chemotherapy. Thus, this study attempted to evaluate ART treatment for anti-glioma. To analyze the cell growth of C6 rat glioma after ART treatment, MTT assay and colony formation assay were conducted. In addition, the scratch and transwell assay was used to investigate the migration and invasion ability after ART treatment. The results showed that ART effectively inhibited the proliferation and colony forming of glioma cells. Moreover, ART suppressed glioma cell migration and invasion. Accordingly, we conclude that ART holds potential for anti-glioma progression, which can be further developed for its therapeutic effectiveness for the survival rate of patient in the future

Alifieris, C., and D.T. Trafalis. 2015. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacology & therapeutics. 152:63-82.
Ashley, E.A., M. Dhorda, R.M. Fairhurst, C. Amaratunga, P. Lim, S. Suon, S. Sreng, J.M. Anderson, S. Mao, and B. Sam. 2014. Spread of artemisinin resistance in Plasmodium falciparum malaria. New england journal of medicine. 371:411-423.
Barnett, G.H. 2007. High-grade gliomas: diagnosis and treatment. Springer Science & Business Media.
Berdelle, N., T. Nikolova, S. Quiros, T. Efferth, and B. Kaina. 2011. Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells. Molecular cancer therapeutics. 10:2224-2233.
Chen, C.-c., Y. Chen, Y.-T. Hsi, C.-S. Chang, L.-F. Huang, C.-T. Ho, T.-D. Way, and J.-Y. Kao. 2013. Chemical constituents and anticancer activity of Curcuma zedoaria roscoe essential oil against non-small cell lung carcinoma cells in vitro and in vivo. Journal of agricultural and food chemistry. 61:11418-11427.
Chen, R., M.C. Nishimura, S.M. Bumbaca, S. Kharbanda, W.F. Forrest, I.M. Kasman, J.M. Greve, R.H. Soriano, L.L. Gilmour, and C.S. Rivers. 2010. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer cell. 17:362-375.
Collins, T.J. 2007. ImageJ for microscopy. BioTechniques. 43:25-30.
Davis, T.M., T.Q. Binh, K.F. Ilett, K.T. Batty, H.L. Phuong, G.M. Chiswell, V.D. Phuong, and C. Agus. 2003. Penetration of dihydroartemisinin into cerebrospinal fluid after administration of intravenous artesunate in severe falciparum malaria. Antimicrobial agents and chemotherapy. 47:368-370.
DeAngelis, L.M. 2001. Brain tumors. New england journal of medicine. 344:114-123.
Delgado-Lopez, P., and E. Corrales-Garcia. 2016. Survival in glioblastoma: a review on the impact of treatment modalities. Clinical and translational oncology. 18:1062-1071.
Demuth, T., and M.E. Berens. 2004. Molecular mechanisms of glioma cell migration and invasion. Journal of neuro-oncology. 70:217-228.
Efferth, T., H. Dunstan, A. Sauerbrey, H. Miyachi, and C.R. Chitambar. 2001. The anti-malarial artesunate is also active against cancer. International journal of oncology. 18:767-773.
Efferth, T., T. Ramirez, E. Gebhart, and M.-E. Halatsch. 2004. Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochemical pharmacology. 67:1689-1700.
Ellor, S.V., T.A. Pagano-Young, and N.G. Avgeropoulos. 2014. Glioblastoma: background, standard treatment paradigms, and supportive care considerations. SAGE Publications Sage CA: Los Angeles, CA.
Eyler, C.E., and J.N. Rich. 2008. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 26:2839.
Ford, E., S. Catt, A. Chalmers, and L. Fallowfield. 2012. Systematic review of supportive care needs in patients with primary malignant brain tumors. Neuro-oncology. 14:392-404.
Fu, D., J.A. Calvo, and L.D. Samson. 2012. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nature reviews cancer. 12:104.
Giese, A., M.D. Rief, M.A. Loo, and M.E. Berens. 1994. Determinants of human astrocytoma migration. Cancer research. 54:3897-3904.
Gilbert, M.R., M. Wang, K.D. Aldape, R. Stupp, M.E. Hegi, K.A. Jaeckle, T.S. Armstrong, J.S. Wefel, M. Won, and D.T. Blumenthal. 2013. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. Journal of clinical oncology. 31:4085.
Graham, C.H., I. Connelly, J.R. MacDougall, R.S. Kerbel, W.G. Stetler-Stevenson, and P.K. Lala. 1994. Resistance of malignant trophoblast cells to both the anti-proliferative and anti-invasive effects of transforming growth factor-beta. Experimental cell research. 214:93-99.
Grossman, S.A., X. Ye, S. Piantadosi, S. Desideri, L.B. Nabors, M. Rosenfeld, J. Fisher, and N.C. Consortium. 2010. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clinical cancer research. 16:2443-2449.
Guan, X., J. Vengoechea, S. Zheng, A.E. Sloan, Y. Chen, D.J. Brat, B.P. O’Neill, J. De Groot, S. Yust-Katz, and W.-K.A.J.P.o. Yung. 2014. Molecular subtypes of glioblastoma are relevant to lower grade glioma. PloS one. 9:e91216.
Guo, Z. 2016. Artemisinin anti-malarial drugs in China. Acta pharmaceutica sinica. b. 6:115-124.
Hamacher-Brady, A., H.A. Stein, S. Turschner, I. Toegel, R. Mora, N. Jennewein, T. Efferth, R. Eils, and N.R. Brady. 2011. Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production. Journal of biological chemistry. 286:6587-6601.
Hanif, F., K. Muzaffar, K. Perveen, S.M. Malhi, and S.U. Simjee. 2017. Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pacific journal of cancer prevention: APJCP. 18:3.
Hartmann, C., J. Meyer, J. Balss, D. Capper, W. Mueller, A. Christians, J. Felsberg, M. Wolter, C. Mawrin, W. Wick, M. Weller, C. Herold-Mende, A. Unterberg, J.W. Jeuken, P. Wesseling, G. Reifenberger, and A. von Deimling. 2009. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica. 118:469-474.
Hegi, M.E., A.-C. Diserens, T. Gorlia, M.-F. Hamou, N. De Tribolet, M. Weller, J.M. Kros, J.A. Hainfellner, W. Mason, and L. Mariani. 2005. MGMT gene silencing and benefit from temozolomide in glioblastoma. New england journal of medicine. 352:997-1003.
Hien, T.T., N.H. Phu, N.T. Mai, T.T. Chau, T.T. Trang, P.P. Loc, B.M. Cuong, N.T. Dung, H. Vinh, D.J. Waller, and et al. 1992. An open randomized comparison of intravenous and intramuscular artesunate in severe falciparum malaria. Transactions of the royal society of tropical medicine and hygiene. 86:584-585.
Hirata, E., Y. Arakawa, M. Shirahata, M. Yamaguchi, Y. Kishi, T. Okada, J.A. Takahashi, M. Matsuda, and N. Hashimoto. 2009. Endogenous tenascin-C enhances glioblastoma invasion with reactive change of surrounding brain tissue. Cancer science. 100:1451-1459.
Hou, J., D. Wang, R. Zhang, and H. Wang. 2008. Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clinical cancer research. 14:5519-5530.
Ilamathi, M., S. Santhosh, and V. Sivaramakrishnan. 2016. Artesunate as an anti-cancer agent targets STAT-3 and favorably suppresses hepatocellular carcinoma. Current topics in medicinal chemistry. 16:2453-2463.
Jenkins, R.B., H. Blair, K.V. Ballman, C. Giannini, R.M. Arusell, M. Law, H. Flynn, S. Passe, S. Felten, P.D. Brown, E.G. Shaw, and J.C. Buckner. 2006. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer research. 66:9852-9861.
Jing, W., H. Dong, M. Min, Z. Runpeng, X. Xuewei, C. Ru, X. Yingru, N. Shengfa, T. Baoxian, Y. Jinbo, H. Weidong, and Z. Rongbo. 2019. Dependence of artesunate on long noncoding RNA-RP11 to inhibit epithelial-mesenchymal transition of hepatocellular carcinoma. Journal of cellular biochemistry. 120:6026-6034.
Jue, T.R., and K.L. McDonald. 2016. The challenges associated with molecular targeted therapies for glioblastoma. Journal of neuro-oncology. 127:427-434.
Karpel-Massler, G., M.A. Westhoff, R.E. Kast, A. Dwucet, L. Nonnenmacher, C.R. Wirtz, K.M. Debatin, and M.E. Halatsch. 2014. Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines. Anti-cancer agents in medicinal chemistry. 14:313-318.
Katsetos, C.D., M.J. Reginato, P.W. Baas, L. D’Agostino, A. Legido, J.A. Tuszyn, E. Draberova, and P. Draber. 2015. Emerging microtubule targets in glioma therapy. Seminars in pediatric neurology. Vol. 22. Elsevier. 49-72.
Khan, A., M. Aqil, S.S. Imam, A. Ahad, Y. Sultana, A. Ali, and K. Khan. 2018. Temozolomide loaded nano lipid based chitosan hydrogel for nose to brain delivery: Characterization, nasal absorption, histopathology and cell line study. International journal of biological macromolecules. 116:1260-1267.
Khan, A., S.S. Imam, M. Aqil, A. Ahad, Y. Sultana, A. Ali, and K. Khan. 2016. Brain targeting of temozolomide via the intranasal route using lipid-based nanoparticles: brain pharmacokinetic and scintigraphic analyses. Molecular pharmaceutics. 13:3773-3782.
Kim, S.-S., A. Rait, E. Kim, K.F. Pirollo, and E.H. Chang. 2015. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. Nanomedicine: nanotechnology, biology and medicine. 11:301-311.
Kotelevets, L., J. van Hengel, E. Bruyneel, M. Mareel, F. van Roy, and E. Chastre. 2001. The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness. Journal of cell biology. 155:1129-1135.
Lai, H., and N.P. Singh. 1995. Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer letters. 91:41-46.
Lai, H., and N.P. Singh. 2006. Oral artemisinin prevents and delays the development of 7, 12-dimethylbenz [a] anthracene (DMBA)-induced breast cancer in the rat. Cancer letters. 231:43-48.
Lam, F.C., S.W. Morton, J. Wyckoff, T.L. Vu Han, M.K. Hwang, A. Maffa, E. Balkanska-Sinclair, M.B. Yaffe, S.R. Floyd, and P.T. Hammond. 2018. Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Nature communications. 9:1991.
Lee, C.Y. 2017. Strategies of temozolomide in future glioblastoma treatment. OncoTargets and therapy. 10:265.
Li, Y., L. Feng, Y. Li, W. Jiang, N. Shan, and X. Wang. 2014. Artesunate possesses anti-leukemia properties that can be enhanced by arsenic trioxide. Leukemia & lymphoma. 55:1366-1372.
Lian, S., R. Shi, X. Huang, X. Hu, B. Song, Y. Bai, B. Yang, J. Dong, Z. Du, Y. Zhang, J. Jia, N. Ma, G. Guo, and M. Wang. 2016. Artesunate attenuates glioma proliferation, migration and invasion by affecting cellular mechanical properties. Oncology reports. 36:984-990.
Liao, Y.X., Z.P. Zhang, J. Zhao, and J.P. Liu. 2018. Effects of Fibronectin 1 on Cell Proliferation, Senescence and Apoptosis of Human Glioma Cells Through the PI3K/AKT Signaling Pathway. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 48:1382-1396.
Liu, L., L.F. Zuo, J. Zuo, and J. Wang. 2015. Artesunate induces apoptosis and inhibits growth of Eca109 and Ec9706 human esophageal cancer cell lines in vitro and in vivo. Molecular medicine reports. 12:1465-1472.
Mariani, L., C. Beaudry, W.S. McDonough, D.B. Hoelzinger, T. Demuth, K.R. Ross, T. Berens, S.W. Coons, G. Watts, J.M. Trent, J.S. Wei, A. Giese, and M.E. Berens. 2001. Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation genes: a cDNA microarray analysis. Journal of neuro-oncology. 53:161-176.
Marshall, J. 2011. Transwell((R)) invasion assays. Methods in molecular biology (Clifton, N.J.). 769:97-110.
Mercer, A.E., I.M. Copple, J.L. Maggs, P.M. O'Neill, and B.K. Park. 2011. The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials. Journal of biological chemistry. 286:987-996.
Meshnick, S.R., T.E. Taylor, and S. Kamchonwongpaisan. 1996. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiological reviews. 60:301-315.
Miller, R.S., Q. Li, L.R. Cantilena, K.J. Leary, G.A. Saviolakis, V. Melendez, B. Smith, and P.J. Weina. 2012. Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: phase 1b study. Malaria journal. 11:255.
Nam, W., J. Tak, J.K. Ryu, M. Jung, J.I. Yook, H.J. Kim, and I.H. Cha. 2007. Effects of artemisinin and its derivatives on growth inhibition and apoptosis of oral cancer cells. Head & neck. 29:335-340.
Newlands, E., G. Blackledge, J. Slack, G. Rustin, D. Smith, N. Stuart, C. Quarterman, R. Hoffman, M. Stevens, and M. Brampton. 1992. Phase i trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). British journal of cancer. 65:287.
Nollet, F., P. Kools, and F. van Roy. 2000. Phylogenetic analysis of the cadherin superfamily allows identification of six major subfamilies besides several solitary members. Journal of molecular biology. 299:551-572.
Organization, W.H. 2015. Guidelines for the treatment of malaria. World Health Organization.
Ostrom, Q.T., H. Gittleman, J. Fulop, M. Liu, R. Blanda, C. Kromer, Y. Wolinsky, C. Kruchko, and J.S.J.N.-o. Barnholtz-Sloan. 2015. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-oncology. 17 Suppl 4:iv1-iv62.
Paolillo, M., C. Boselli, and S. Schinelli. 2018. Glioblastoma under siege: an overview of current therapeutic strategies. Brain sciences. 8:15.
Patchell, R.A. 2003. The management of brain metastases. Cancer treatment reviews. 29:533-540.
Prados, M.D., S.A. Byron, N.L. Tran, J.J. Phillips, A.M. Molinaro, K.L. Ligon, P.Y. Wen, J.G. Kuhn, I.K. Mellinghoff, and J.F. De Groot. 2015. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-oncology. 17:1051-1063.
Price, R.N. 2000. Artemisinin drugs: novel antimalarial agents. Expert opinion on investigational drugs. 9:1815-1827.
Qazi, M.A., P. Vora, C. Venugopal, S.S. Sidhu, J. Moffat, C. Swanton, and S.K. Singh. 2017. Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. Annals of oncology : official journal of the European Society for Medical Oncology. 28:1448-1456.
Reichert, S., V. Reinboldt, S. Hehlgans, T. Efferth, C. Rodel, and F. Rodel. 2012. A radiosensitizing effect of artesunate in glioblastoma cells is associated with a diminished expression of the inhibitor of apoptosis protein survivin. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 103:394-401.
Rempel, S.A., W.A. Golembieski, S. Ge, N. Lemke, K. Elisevich, T. Mikkelsen, and J.A. Gutierrez. 1998. SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. Journal of neuropathology and experimental neurology. 57:1112-1121.
Robert, A., Y. Coppel, and B. Meunier. 2002. Alkylation of heme by the antimalarial drug artemisinin. Chemical communications (Cambridge, England):414-415.
Rutka, J.T., G. Apodaca, R. Stern, and M. Rosenblum. 1988. The extracellular matrix of the central and peripheral nervous systems: structure and function. Journal of neurosurgery. 69:155-170.
Saika, K., and K. Katanoda. 2011. Comparison of time trends in brain and central nervous system cancer mortality (1990–2006) between countries based on the WHO mortality database. Japanese journal of clinical oncology. 41:304-305.
Seno, T., H. Harada, S. Kohno, M. Teraoka, A. Inoue, and T. Ohnishi. 2009. Downregulation of SPARC expression inhibits cell migration and invasion in malignant gliomas. International journal of oncology. 34:707-715.
Soomro, S.H., L.R. Ting, Y.Y. Qing, and M.J.J.P.M.A. Ren. 2017. Molecular biology of glioblastoma: Classification and mutational locations. Journal of pakistan medical association. 67:1410-1414.
Sørensen, M.D., S. Fosmark, S. Hellwege, D. Beier, B.W. Kristensen, and C.P. Beier. 2015. Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma. Advances in experimental medicine and biology. 853:111-138.
Stupp, R., W.P. Mason, M.J. Van Den Bent, M. Weller, B. Fisher, M.J. Taphoorn, K. Belanger, A.A. Brandes, C. Marosi, and U. Bogdahn. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New england journal of medicine. 352:987-996.
Taga, T., A. Suzuki, I. Gonzalez-Gomez, F.H. Gilles, M. Stins, H. Shimada, L. Barsky, K.I. Weinberg, and W.E. Laug. 2002. alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. International journal of cancer. 98:690-697.
Tanaka, H., W. Putalun, W. De-Eknamkul, O. Matangkasombut, and Y. Shoyama. 2007. Preparation of a novel monoclonal antibody against the antimalarial drugs, artemisinin and artesunate. Planta medica. 73:1127-1132.
Thanaketpaisarn, O., P. Waiwut, H. Sakurai, and I. Saiki. 2011. Artesunate enhances TRAIL-induced apoptosis in human cervical carcinoma cells through inhibition of the NF-kappaB and PI3K/Akt signaling pathways. International journal of oncology. 39:279-285.
Theeler, B.J., and M.R. Gilbert. 2015. Advances in the treatment of newly diagnosed glioblastoma. BMC medicine. 13:293.
Tu, Y. 2016. Artemisinin—A gift from traditional Chinese medicine to the world (Nobel lecture). Angewandte chemie international edition. 55:10210-10226.
Van Tellingen, O., B. Yetkin-Arik, M. De Gooijer, P. Wesseling, T. Wurdinger, and H. De Vries. 2015. Overcoming the blood–brain tumor barrier for effective glioblastoma treatment. Drug resistance updates. 19:1-12.
Vatsveen, T.K., M.R. Myhre, C.B. Steen, S. Walchli, O.C. Lingjaerde, B. Bai, P. Dillard, T.A. Theodossiou, T. Holien, A. Sundan, E.M. Inderberg, E.B. Smeland, J.H. Myklebust, and M.P. Oksvold. 2018. Artesunate shows potent anti-tumor activity in B-cell lymphoma. Journal of hematology & oncology. 11:23.
Villano, J.L., T.E. Seery, and L.R. Bressler. 2009. Temozolomide in malignant gliomas: current use and future targets. Cancer chemotherapy and pharmacology. 64:647-655.
Wang, N., H. Chen, Y. Teng, X. Ding, H. Wu, and X. Jin. 2017a. Artesunate inhibits proliferation and invasion of mouse hemangioendothelioma cells in vitro and of tumor growth in vivo. Oncology letters. 14:6170-6176.
Wang, Q., L.M. Wu, Y. Zhao, X.L. Zhang, and N.P. Wang. 2002. [The anticancer effect of artesunate and its mechanism]. Yao xue xue bao = Acta pharmaceutica sinica. 37:477-478.
Wang, X., Q. Du, Z. Mao, X. Fan, B. Hu, Z. Wang, Z. Chen, X. Jiang, Z. Wang, and N. Lei. 2017b. Combined treatment with artesunate and bromocriptine has synergistic anticancer effects in pituitary adenoma cell lines. Oncotarget. 8:45874.
Wen, P.Y., and S.J.N.E.J.o.M. Kesari. 2008. Malignant gliomas in adults. New england journal of medicine. 359:492-507.
Weng, X., S. Zhu, and H. Cui. 2018. Artesunate inhibits proliferation of glioblastoma cells by arresting cell cycle. Zhongguo Zhong yao za zhi= Zhongguo zhongyao zazhi= China journal of Chinese materia medica. 43:772-778.
White, N.J. 2008. Qinghaosu (artemisinin): the price of success. Science (New York, N.Y.). 320:330-334.
Yan, H., D.W. Parsons, G. Jin, R. McLendon, B.A. Rasheed, W. Yuan, I. Kos, I. Batinic-Haberle, S. Jones, G.J. Riggins, H. Friedman, A. Friedman, D. Reardon, J. Herndon, K.W. Kinzler, V.E. Velculescu, B. Vogelstein, and D.D. Bigner. 2009. IDH1 and IDH2 mutations in gliomas. New england journal of medicine. 360:765-773.
Yang, N.D., S.H. Tan, S. Ng, Y. Shi, J. Zhou, K.S. Tan, W.S. Wong, and H.M. Shen. 2014. Artesunate induces cell death in human cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin. Journal of biological chemistry. 289:33425-33441.
Yang, W., N.M. Warrington, S.J. Taylor, P. Whitmire, E. Carrasco, K.W. Singleton, N. Wu, J.D. Lathia, M.E. Berens, A.H. Kim, J.S. Barnholtz-Sloan, K.R. Swanson, J. Luo, and J.B. Rubin. 2019. Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data. Science translational medicine. 11.
Yokota, J. 2000. Tumor progression and metastasis. Carcinogenesis. 21:497-503.
Zhang, F., D.K. Gosser, Jr., and S.R. Meshnick. 1992. Hemin-catalyzed decomposition of artemisinin (qinghaosu). Biochemical pharmacology. 43:1805-1809.
Zhang, S., and G.S. Gerhard. 2008. Heme activates artemisinin more efficiently than hemin, inorganic iron, or hemoglobin. Bioorganic & medicinal chemistry. 16:7853-7861.
Zhao, X., X. Guo, W. Yue, J. Wang, J. Yang, and J. Chen. 2017. Artemether suppresses cell proliferation and induces apoptosis in diffuse large B cell lymphoma cells. Experimental and therapeutic medicine. 14:4083-4090.
Zhou, X., W.J. Sun, W.M. Wang, K. Chen, J.H. Zheng, M.D. Lu, P.H. Li, and Z.Q. Zheng. 2013. Artesunate inhibits the growth of gastric cancer cells through the mechanism of promoting oncosis both in vitro and in vivo. Anti-cancer drugs. 24:920-927.
Zuo, S., Q. Li, X. Liu, H. Feng, and Y. Chen. 2016. The potential therapeutic effects of artesunate on stroke and other central nervous system diseases. BioMed research international. 2016:1489050.